Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Advances in treatment formulations for acute myeloid leukemia.

Briot T, Roger E, Thépot S, Lagarce F.

Drug Discov Today. 2018 Jun 2. pii: S1359-6446(18)30085-0. doi: 10.1016/j.drudis.2018.05.040. [Epub ahead of print] Review.

PMID:
29870791
2.

Allogeneic stem cell transplantation recipients requiring intensive care: time is of the essence.

Orvain C, Beloncle F, Hamel JF, Del Galy AS, Thépot S, Mercier M, Kouatchet A, Farhi J, Francois S, Ifrah N, Mercat A, Asfar P, Hunault-Berger M, Tanguy-Schmidt A.

Ann Hematol. 2018 May 2. doi: 10.1007/s00277-018-3320-y. [Epub ahead of print]

PMID:
29717367
3.

Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase.

Mollard LM, Chauveau A, Boyer-Perrard F, Douet-Guilbert N, Houot R, Quintin-Roué I, Couturier MA, Dagorne A, Malou M, Le Calloch R, Luycx O, Thepot S, Hunault M, Guillerm G, Berthou C, Ugo V, Lippert É, Ianotto JC.

Leuk Lymphoma. 2018 Apr 4:1-9. doi: 10.1080/10428194.2018.1441408. [Epub ahead of print]

PMID:
29616837
4.

Developmental Trajectories of Hand Movements in Typical Infants and Those at Risk of Developmental Disorders: An Observational Study of Kinematics during the First Year of Life.

Ouss L, Le Normand MT, Bailly K, Leitgel Gille M, Gosme C, Simas R, Wenke J, Jeudon X, Thepot S, Da Silva T, Clady X, Thoueille E, Afshar M, Golse B, Guergova-Kuras M.

Front Psychol. 2018 Feb 19;9:83. doi: 10.3389/fpsyg.2018.00083. eCollection 2018.

5.

Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).

Falantes J, Pleyer L, Thépot S, Almeida AM, Maurillo L, Martínez-Robles V, Stauder R, Itzykson R, Pinto R, Venditti A, Bargay J, Burgstaller S, Martínez MP, Seegers V, Cortesão E, Foncillas MÁ, Gardin C, Montesinos P, Musto P, Fenaux P, Greil R, Sanz MA, Ramos F; European ALMA + Investigators.

Leuk Lymphoma. 2018 May;59(5):1113-1120. doi: 10.1080/10428194.2017.1365854. Epub 2017 Aug 24.

PMID:
28838276
6.

Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial.

Bergeron A, Chevret S, Granata A, Chevallier P, Vincent L, Huynh A, Tabrizi R, Labussiere-Wallet H, Bernard M, Chantepie S, Bay JO, Thiebaut-Bertrand A, Thepot S, Contentin N, Fornecker LM, Maillard N, Risso K, Berceanu A, Blaise D, Peffault de La Tour R, Chien JW, Coiteux V, Socié G; ALLOZITHRO Study Investigators.

JAMA. 2017 Aug 8;318(6):557-566. doi: 10.1001/jama.2017.9938.

7.

Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.

Almeida AM, Prebet T, Itzykson R, Ramos F, Al-Ali H, Shammo J, Pinto R, Maurillo L, Wetzel J, Musto P, Van De Loosdrecht AA, Costa MJ, Esteves S, Burgstaller S, Stauder R, Autzinger EM, Lang A, Krippl P, Geissler D, Falantes JF, Pedro C, Bargay J, Deben G, Garrido A, Bonanad S, Diez-Campelo M, Thepot S, Ades L, Sperr WR, Valent P, Fenaux P, Sekeres MA, Greil R, Pleyer L.

Int J Mol Sci. 2017 Apr 14;18(4). pii: E837. doi: 10.3390/ijms18040837.

8.

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.

Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Balleari E, Kaivers J, Sapena R, Götze K, Müller-Thomas C, Beyne-Rauzy O, Stamatoullas A, Kotsianidis I, Komrokji R, Steensma DP, Fensterl J, Roboz GJ, Bernal T, Ramos F, Calabuig M, Guerci-Bresler A, Bordessoule D, Cony-Makhoul P, Cheze S, Wattel E, Rose C, Vey N, Gioia D, Ferrero D, Gaidano G, Cametti G, Pane F, Sanna A, Germing U, Sanz GF, Dreyfus F, Fenaux P.

J Clin Oncol. 2017 May 10;35(14):1591-1597. doi: 10.1200/JCO.2016.71.3271. Epub 2017 Mar 28.

PMID:
28350519
9.

A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.

Thépot S, Ben Abdelali R, Chevret S, Renneville A, Beyne-Rauzy O, Prébet T, Park S, Stamatoullas A, Guerci-Bresler A, Cheze S, Tertian G, Choufi B, Legros L, Bastié JN, Delaunay J, Chaury MP, Sanhes L, Wattel E, Dreyfus F, Vey N, Chermat F, Preudhomme C, Fenaux P, Gardin C; Groupe Francophone des Myélodysplasies (GFM).

Haematologica. 2016 Aug;101(8):918-25. doi: 10.3324/haematol.2015.140988. Epub 2016 May 26.

10.

Different Impact of the Number of Organ Failures and Graft-Versus-Host Disease on the Outcome of Allogeneic Stem Cell Transplantation Recipients Requiring Intensive Care.

Orvain C, Beloncle F, Hamel JF, Thépot S, Mercier M, Kouatchet A, Farhi J, Francois S, Guardiola P, Asfar P, Hunault-Berger M, Mercat A, Ifrah N, Tanguy-Schmidt A.

Transplantation. 2017 Feb;101(2):437-444. doi: 10.1097/TP.0000000000001143.

PMID:
26950729
11.

Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities.

Wanquet A, Prebet T, Berthon C, Sebert M, Roux C, Kulasekararaj A, Micol JB, Esterni B, Itzykson R, Thepot S, Recher C, Delaunay J, Dreyfus F, Mufti G, Fenaux P, Vey N.

Am J Hematol. 2015 Oct;90(10):859-63. doi: 10.1002/ajh.24099. Epub 2015 Jul 14.

12.

Dearth of polymorphism associated with a sustained response to selection for flowering time in maize.

Durand E, Tenaillon MI, Raffoux X, Thépot S, Falque M, Jamin P, Bourgais A, Ressayre A, Dillmann C.

BMC Evol Biol. 2015 Jun 7;15:103. doi: 10.1186/s12862-015-0382-5.

13.

Diversifying mechanisms in the on-farm evolution of crop mixtures.

Thomas M, Thépot S, Galic N, Jouanne-Pin S, Remoué C, Goldringer I.

Mol Ecol. 2015 Jun;24(12):2937-54. doi: 10.1111/mec.13214. Epub 2015 Jun 5.

PMID:
25913177
14.

Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.

Harel S, Cherait A, Berthon C, Willekens C, Park S, Rigal M, Brechignac S, Thépot S, Quesnel B, Gardin C, Adès L, Fenaux P, Braun T.

Leuk Res. 2015 May;39(5):501-4. doi: 10.1016/j.leukres.2015.02.004. Epub 2015 Feb 16.

PMID:
25735917
15.

Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction.

Ramos F, Thépot S, Pleyer L, Maurillo L, Itzykson R, Bargay J, Stauder R, Venditti A, Seegers V, Martínez-Robles V, Burgstaller S, Récher C, Debén G, Gaidano G, Gardin C, Musto P, Greil R, Sánchez-Guijo F, Fenaux P; European ALMA Investigators.

Leuk Res. 2015 Mar;39(3):296-306. doi: 10.1016/j.leukres.2014.12.013. Epub 2014 Dec 31.

PMID:
25601157
16.

Azacitidine for the treatment of relapsed and refractory AML in older patients.

Itzykson R, Thépot S, Berthon C, Delaunay J, Bouscary D, Cluzeau T, Turlure P, Prébet T, Dartigeas C, Marolleau JP, Recher C, Plantier I, Stamatoullas A, Devidas A, Taksin AL, Guièze R, Caillot D, Vey N, Adès L, Ifrah N, Dombret H, Fenaux P, Gardin C.

Leuk Res. 2015 Feb;39(2):124-30. doi: 10.1016/j.leukres.2014.11.009. Epub 2014 Nov 24.

PMID:
25524177
17.

A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.

Thepot S, Boehrer S, Seegers V, Prebet T, Beyne-Rauzy O, Wattel E, Delaunay J, Raffoux E, Hunault M, Jourdan E, Chermat F, Sebert M, Kroemer G, Fenaux P, Adès L; Groupe Francophone des Myelodysplasies (GFM).

Leuk Res. 2014 Dec;38(12):1430-4. doi: 10.1016/j.leukres.2014.09.014. Epub 2014 Oct 7.

PMID:
25449687
18.

Efficiently tracking selection in a multiparental population: the case of earliness in wheat.

Thépot S, Restoux G, Goldringer I, Hospital F, Gouache D, Mackay I, Enjalbert J.

Genetics. 2015 Feb;199(2):609-23. doi: 10.1534/genetics.114.169995. Epub 2014 Nov 17.

19.

When the eye gives it all: diagnosis of relapsing acute myeloblastic leukemia with anterior chamber tap of a chronic hypopyon.

Touitou V, Bodaghi B, Thepot S, Chapiro E, Nguyen-Khac F, Charlotte F, LeHoang P, Maloum K.

Am J Hematol. 2014 Aug;89(8):858-9. No abstract available.

PMID:
25165787
20.

Azacitidine in untreated acute myeloid leukemia: a report on 149 patients.

Thépot S, Itzykson R, Seegers V, Recher C, Raffoux E, Quesnel B, Delaunay J, Cluzeau T, Marfaing Koka A, Stamatoullas A, Chaury MP, Dartigeas C, Cheze S, Banos A, Morel P, Plantier I, Taksin AL, Marolleau JP, Pautas C, Thomas X, Isnard F, Beve B, Chait Y, Guerci A, Vey N, Dreyfus F, Ades L, Ifrah N, Dombret H, Fenaux P, Gardin C; Groupe Francophone des Myélodysplasies (GFM), Acute Leukemia French Association (ALFA); Groupe Ouest-Est des Leucémies Aiguës; Maladies du Sang (GOELAMS).

Am J Hematol. 2014 Apr;89(4):410-6. doi: 10.1002/ajh.23654. Epub 2014 Feb 6.

21.

Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM).

Bally C, Thépot S, Quesnel B, Vey N, Dreyfus F, Fadlallah J, Turlure P, de Botton S, Dartigeas C, de Renzis B, Itzykson R, Fenaux P, Adès L.

Leuk Res. 2013 Jun;37(6):637-40. doi: 10.1016/j.leukres.2013.02.014. Epub 2013 Mar 15.

PMID:
23499498
22.

The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience.

Lamarque M, Raynaud S, Itzykson R, Thepot S, Quesnel B, Dreyfus F, Rauzy OB, Turlure P, Vey N, Recher C, Dartigeas C, Legros L, Delaunay J, Visanica S, Stamatoullas A, Fenaux P, Adès L.

Blood. 2012 Dec 13;120(25):5084-5. doi: 10.1182/blood-2012-09-453555. No abstract available. Erratum in: Blood. 2014 Jun 26;123(26):4152.

23.

Erlotinib antagonizes ABC transporters in acute myeloid leukemia.

Lainey E, Sébert M, Thépot S, Scoazec M, Bouteloup C, Leroy C, De Botton S, Galluzzi L, Fenaux P, Kroemer G.

Cell Cycle. 2012 Nov 1;11(21):4079-92. doi: 10.4161/cc.22382. Epub 2012 Oct 24.

24.

Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure.

Prébet T, Thepot S, Gore SD, Dreyfus F, Fenaux P, Vey N.

Haematologica. 2013 Feb;98(2):e18-9. doi: 10.3324/haematol.2012.071050. Epub 2012 Sep 14. No abstract available.

25.

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort.

Itzykson R, Thépot S, Quesnel B, Dreyfus F, Recher C, Wattel E, Gardin C, Adès L, Fenaux P.

Blood. 2012 Jun 21;119(25):6172-3. doi: 10.1182/blood-2012-04-422204. No abstract available.

26.

Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure.

Prébet T, Gore SD, Thépot S, Esterni B, Quesnel B, Beyne Rauzy O, Dreyfus F, Gardin C, Fenaux P, Vey N.

Br J Haematol. 2012 Jun;157(6):764-6. doi: 10.1111/j.1365-2141.2012.09076.x. Epub 2012 Mar 6. No abstract available.

27.

Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

Itzykson R, Thépot S, Beyne-Rauzy O, Ame S, Isnard F, Dreyfus F, Salanoubat C, Taksin AL, Chelgoum Y, Berthon C, Malfuson JV, Legros L, Vey N, Turlure P, Gardin C, Boehrer S, Ades L, Fenaux P; Groupe Francophone des Myelodysplasies (GFM).

Leuk Res. 2012 Apr;36(4):397-400. doi: 10.1016/j.leukres.2011.11.019. Epub 2011 Dec 15.

PMID:
22177456
28.

Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia.

Tailler M, Senovilla L, Lainey E, Thépot S, Métivier D, Sébert M, Baud V, Billot K, Fenaux P, Galluzzi L, Boehrer S, Kroemer G, Kepp O.

Oncogene. 2012 Jul 26;31(30):3536-46. doi: 10.1038/onc.2011.521. Epub 2011 Nov 21.

PMID:
22105358
29.

Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia.

Boehrer S, Galluzzi L, Lainey E, Bouteloup C, Tailler M, Harper F, Pierron G, Adès L, Thépot S, Sébert M, Gardin C, de Botton S, Fenaux P, Kroemer G.

Cell Cycle. 2011 Sep 15;10(18):3168-75. Epub 2011 Sep 15.

PMID:
21897118
30.

Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.

Prébet T, Gore SD, Esterni B, Gardin C, Itzykson R, Thepot S, Dreyfus F, Rauzy OB, Recher C, Adès L, Quesnel B, Beach CL, Fenaux P, Vey N.

J Clin Oncol. 2011 Aug 20;29(24):3322-7. doi: 10.1200/JCO.2011.35.8135. Epub 2011 Jul 25.

31.

Tyrosine kinase inhibitors for the treatment of acute myeloid leukemia: delineation of anti-leukemic mechanisms of action.

Lainey E, Thépot S, Bouteloup C, Sébert M, Adès L, Tailler M, Gardin C, de Botton S, Baruchel A, Fenaux P, Kroemer G, Boehrer S.

Biochem Pharmacol. 2011 Nov 15;82(10):1457-66. doi: 10.1016/j.bcp.2011.05.011. Epub 2011 Jun 1.

PMID:
21664897
32.

Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia.

Thépot S, Lainey E, Cluzeau T, Sébert M, Leroy C, Adès L, Tailler M, Galluzzi L, Baran-Marszak F, Roudot H, Eclache V, Gardin C, de Botton S, Auberger P, Fenaux P, Kroemer G, Boehrer S.

Cell Cycle. 2011 Jul 15;10(14):2323-30. Epub 2011 Jul 15.

PMID:
21654193
33.

Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine.

Itzykson R, Thépot S, Eclache V, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, Vey N, Recher C, Boehrer S, Gardin C, Adès L, Fenaux P; Groupe Francophone des Myelodysplasies (GFM).

Leukemia. 2011 Jul;25(7):1207-9. doi: 10.1038/leu.2011.63. Epub 2011 Apr 5. No abstract available.

PMID:
21468040
34.

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

Itzykson R, Thépot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, Vey N, Recher C, Dartigeas C, Legros L, Delaunay J, Salanoubat C, Visanica S, Stamatoullas A, Isnard F, Marfaing-Koka A, de Botton S, Chelghoum Y, Taksin AL, Plantier I, Ame S, Boehrer S, Gardin C, Beach CL, Adès L, Fenaux P; Groupe Francophone des Myelodysplasies(GFM).

Blood. 2011 Jan 13;117(2):403-11. doi: 10.1182/blood-2010-06-289280. Epub 2010 Oct 12.

35.

The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation.

Thepot S, Zhou J, Perrot A, Robin M, Xhaard A, de Latour RP, Ades L, Ribaud P, Petropoulou AD, Porcher R, Socié G.

Leukemia. 2010 Nov;24(11):1852-8. doi: 10.1038/leu.2010.187. Epub 2010 Sep 9.

PMID:
20827288
36.

Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).

Thepot S, Itzykson R, Seegers V, Raffoux E, Quesnel B, Chait Y, Sorin L, Dreyfus F, Cluzeau T, Delaunay J, Sanhes L, Eclache V, Dartigeas C, Turlure P, Harel S, Salanoubat C, Kiladjian JJ, Fenaux P, Adès L; Groupe Francophone des Myelodysplasies (GFM).

Blood. 2010 Nov 11;116(19):3735-42. doi: 10.1182/blood-2010-03-274811. Epub 2010 Jul 27.

37.

Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: decreasing dosage does not alter serum IgG levels.

Thépot S, Malphettes M, Gardeur A, Galicier L, Asli B, Karlin L, Gérard L, Laumont R, Doize ML, Arnulf B, Fieschi C, Bengoufa D, Oksenhendler E.

J Clin Immunol. 2010 Jul;30(4):602-6. doi: 10.1007/s10875-010-9417-2.

PMID:
20393788
38.

Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup.

Prébet T, Boissel N, Reutenauer S, Thomas X, Delaunay J, Cahn JY, Pigneux A, Quesnel B, Witz F, Thépot S, Ugo V, Terre C, Recher C, Tavernier E, Hunault M, Esterni B, Castaigne S, Guilhot F, Dombret H, Vey N; Acute Leukemia French Association; Groupe Ouest-Est des leucémies et autres maladies du sang (GOELAMS); Core Binding Factor Acute Myeloid Leukemia (CBF AML) intergroup.

J Clin Oncol. 2009 Oct 1;27(28):4747-53. doi: 10.1200/JCO.2008.21.0674. Epub 2009 Aug 31.

PMID:
19720919
39.

Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome.

Boehrer S, Adès L, Tajeddine N, Hofmann WK, Kriener S, Bug G, Ottmann OG, Ruthardt M, Galluzzi L, Fouassier C, Tailler M, Olaussen KA, Gardin C, Eclache V, de Botton S, Thepot S, Fenaux P, Kroemer G.

Oncogene. 2009 Jun 4;28(22):2205-18. doi: 10.1038/onc.2009.69. Epub 2009 Apr 27.

PMID:
19398952

Supplemental Content

Loading ...
Support Center